PUBLISHER: TechNavio | PRODUCT CODE: 1908435
PUBLISHER: TechNavio | PRODUCT CODE: 1908435
The global cytomegalovirus (cmv) therapeutics market is forecasted to grow by USD 305.6 mn during 2025-2030, accelerating at a CAGR of 4.7% during the forecast period. The report on the global cytomegalovirus (cmv) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of immunocompromised populations and transplant procedures, transition toward novel mechanisms of action and improved safety profiles, advancements in diagnostic technologies and prophylactic standards.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2026 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 4.5% |
| CAGR | 4.7% |
| Incremental Value | $305.6 mn |
Technavio's global cytomegalovirus (cmv) therapeutics market is segmented as below:
By Route Of Administration
By End-User
By Therapy
Geography
This study identifies the rise of adoptive cell therapies and virus-specific t-cells as biological modality as one of the prime reasons driving the global cytomegalovirus (cmv) therapeutics market growth during the next few years. Also, emergence of mrna technology and prophylactic vaccine development and strategic prioritization of oral formulations for long-term outpatient management will lead to sizable demand in the market.
The report on the global cytomegalovirus (cmv) therapeutics market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global cytomegalovirus (cmv) therapeutics market vendors that include Astellas Pharma Inc., AstraZeneca Plc, Bausch Lomb Corp., Clinigen Group Plc, Exela Pharma Sciences LLC, F. Hoffmann La Roche Ltd., Fortress Biotech Inc., Fresenius SE and Co. KGaA, Genentech Inc., Gilead Sciences Inc., Jazz Pharmaceuticals Plc, Merck and Co. Inc., Takeda Pharmaceutical Ltd., Teva Pharmaceutical Ltd., Thermo Fisher Scientific Inc., UbiVac, VBI Vaccines Inc.. Also, the global cytomegalovirus (cmv) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.